Kaken Pharmaceutical’s Artz Expands Market
This article was originally published in PharmAsia News
Executive Summary
Kaken Pharmaceutical estimated a seven percent increase in company business operation profit for the fiscal year ending March 2009. However, Daiwa Securities analysis projected a nine percent increase and predicted stable growth for the company's best selling product Artz amid the current economic downturn. Artz is a viscoelastic supplement injection to replace synovial fluid in osteoarthritic knees. Daiwa cited that the number of the patients for the drug is increasing due to a progressively aging population, and as awareness of the treatment increases among potential patients, the market basis for the drug will also expand. (Click here for more - Japanese language